Albireo to Present at Upcoming Investor Conferences
Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in upcoming investor conferences. Ron Cooper, CEO, and Simon Harford, CFO, will present at the Jefferies London Healthcare Conference on November 17 at 11:20 a.m. GMT. Additionally, a pre-recorded fireside chat will be available at the Piper Sandler 33rd Annual Virtual Healthcare Conference starting November 22 at 10:00 a.m. ET. Webcasts will be accessible via Albireo's website.
- None.
- None.
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences:
- Jefferies London Healthcare Conference
Wednesday, November 17 at 11:20 a.m. GMT / 6:20 a.m. ET
- Piper Sandler 33rd Annual Virtual Healthcare Conference
A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22 at 10:00 a.m. ET
The webcasts of the presentations will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the live Jefferies webcast, it is recommended that users register at least 15 minutes prior to the scheduled start times. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 30 days following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay™ (odevixibat), was approved by the U.S. FDA as the first drug for the treatment of pruritus in patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC in patients 6 months or older and has been submitted for pricing and reimbursement approval. The Company is progressing a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.
Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lauren Sneider, 857-300-1737, lauren.sneider@albireopharma.com
Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578
FAQ
What is Albireo Pharma's presentation schedule for November 2021?
Where can I watch Albireo Pharma's investor presentations?
What is the focus of Albireo Pharma's research and development?
What is Bylvay and its significance for Albireo Pharma?
What are Albireo Pharma's future development plans?
